Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Operating Leases (2019 - 2025)

Voyager Therapeutics (VYGR) has disclosed Operating Leases for 7 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 21.48% to $28.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.7 million through Dec 2025, down 21.48% year-over-year, with the annual reading at $28.7 million for FY2025, 21.48% down from the prior year.
  • Operating Leases hit $28.7 million in Q4 2025 for Voyager Therapeutics, down from $30.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $42.1 million in Q1 2021 to a low of $17.1 million in Q4 2023.
  • Historically, Operating Leases has averaged $30.9 million across 5 years, with a median of $33.6 million in 2025.
  • Biggest five-year swings in Operating Leases: tumbled 47.45% in 2022 and later skyrocketed 115.13% in 2024.
  • Year by year, Operating Leases stood at $38.6 million in 2021, then crashed by 47.44% to $20.3 million in 2022, then dropped by 15.77% to $17.1 million in 2023, then skyrocketed by 113.52% to $36.5 million in 2024, then fell by 21.48% to $28.7 million in 2025.
  • Business Quant data shows Operating Leases for VYGR at $28.7 million in Q4 2025, $30.5 million in Q3 2025, and $32.6 million in Q2 2025.